Statement of Use

PLATO

AVROBIO, Inc.

Trademark/Service Mark Statement of Use

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1553 (Rev 09/2005)
OMB No. 0651-0054 (Exp 12/31/2020)

Trademark/Service Mark Statement of Use
(15 U.S.C. Section 1051(d))


The table below presents the data as entered.

Input Field
Entered
SERIAL NUMBER 88276835
LAW OFFICE ASSIGNED LAW OFFICE 114
EXTENSION OF USE YES
MARK SECTION
MARK http://tmng-al.gov.uspto.report/resting2/api/img/88276835/large
LITERAL ELEMENT PLATO
STANDARD CHARACTERS YES
USPTO-GENERATED IMAGE YES
MARK STATEMENT The mark consists of standard characters, without claim to any particular font style, size or color.
OWNER SECTION (current)
NAME AVROBIO, Inc.
INTERNAL ADDRESS Building 300, Suite 201
STREET One Kendall Square
CITY Cambridge
STATE Massachusetts
ZIP/POSTAL CODE 02139
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY United States
OWNER SECTION (proposed)
NAME AVROBIO, Inc.
INTERNAL ADDRESS Building 300, Suite 201
STREET One Kendall Square
CITY Cambridge
STATE Massachusetts
ZIP/POSTAL CODE 02139
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY United States
EMAIL XXXX
ATTORNEY INFORMATION (current)
NAME Michael J. Belliveau
ATTORNEY BAR MEMBERSHIP NUMBER NOT SPECIFIED
YEAR OF ADMISSION NOT SPECIFIED
U.S. STATE/ COMMONWEALTH/ TERRITORY NOT SPECIFIED
FIRM NAME CLARK+ELBING LLP
STREET 101 FEDERAL STREET, 15TH FLOOR
CITY BOSTON
STATE Massachusetts
POSTAL CODE 02110
COUNTRY/REGION/JURISDICTION/U.S. TERRITORY United States
PHONE 617-428-0200
FAX 6174287045
EMAIL cedocket@clarkelbing.com
DOCKET/REFERENCE NUMBER 51182-T02001
ATTORNEY INFORMATION (proposed)
NAME Michael J. Belliveau
ATTORNEY BAR MEMBERSHIP NUMBER XXX
YEAR OF ADMISSION XXXX
U.S. STATE/ COMMONWEALTH/ TERRITORY XX
FIRM NAME CLARK+ELBING LLP
STREET 101 FEDERAL STREET, 15TH FLOOR
CITY BOSTON
STATE Massachusetts
POSTAL CODE 02110
COUNTRY/REGION/JURISDICTION/U.S. TERRITORY United States
PHONE 617-428-0200
FAX 6174287045
EMAIL cedocket@clarkelbing.com
DOCKET/REFERENCE NUMBER 51182-T02001
OTHER APPOINTED ATTORNEY Paul T. Clark, Karen L. Elbing, James D. DeCamp, Susan M. Michaud, J. Cooper McDonald, Richard Todd Armstrong, Jeffrey J. Ellison, Jan N. Tittel, Andrew R. Germain, Thomas J. Takara, Adil Zhugralin
CORRESPONDENCE INFORMATION (current)
NAME MICHAEL J. BELLIVEAU
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE cedocket@clarkelbing.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) NOT PROVIDED
DOCKET/REFERENCE NUMBER 51182-T02001
CORRESPONDENCE INFORMATION (proposed)
NAME Michael J. Belliveau
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE cedocket@clarkelbing.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) NOT PROVIDED
DOCKET/REFERENCE NUMBER 51182-T02001
GOODS AND/OR SERVICES SECTION
INTERNATIONAL CLASS 005
CURRENT IDENTIFICATION Pharmaceuticals for treatment of rare and other diseases, namely, autoimmune diseases, diseases of the central nervous system, and oncological diseases
GOODS OR SERVICES DELETE ALL ITU GOODS/SERVICES IN THIS CLASS OR PROCESS ACCORDING TO REQUEST TO DIVIDE
INTERNATIONAL CLASS 042
CURRENT IDENTIFICATION Platform as a service (PAAS) featuring gene therapy development platforms for treatments for rare and other diseases
GOODS OR SERVICES KEEP ALL LISTED
FIRST USE ANYWHERE DATE 03/00/2020
FIRST USE IN COMMERCE DATE 03/00/2020
SPECIMEN FILE NAME(S)
       ORIGINAL PDF FILE SPN1-382423194-20200330111050057681_._PLATO.pdf
       CONVERTED PDF FILE(S)
       (2 pages)
\\TICRS\EXPORT18\IMAGEOUT18\889\775\88977547\LM2Copy\88276835\1\SOU14\SOU2.JPG
        \\TICRS\EXPORT18\IMAGEOUT18\889\775\88977547\LM2Copy\88276835\1\SOU14\SOU3.JPG
SPECIMEN DESCRIPTION Image of applicant website showing platform as a service (PAAS) featuring gene therapy development platforms for treatments for rare and other diseases
REQUEST TO DIVIDE YES
GOOD(S)/SERVICE(S) IN USE Platform as a service (PAAS) featuring gene therapy development platforms for treatments for rare and other diseases
GOOD(S)/SERVICES INTENT TO USE Pharmaceuticals for treatment of rare and other diseases, namely, autoimmune diseases, diseases of the central nervous system, and oncological diseases
PAYMENT SECTION
NUMBER OF CLASSES IN USE 1
SUBTOTAL AMOUNT [ALLEGATION OF USE FEE] 100
REQUEST TO DIVIDE FEE 100
TOTAL AMOUNT 200
SIGNATURE SECTION
DECLARATION SIGNATURE /Jan N. Tittel/
SIGNATORY'S NAME Jan N. Tittel
SIGNATORY'S POSITION Attorney of record, Massachusetts bar member
DATE SIGNED 03/31/2020
SIGNATORY'S PHONE NUMBER 6174280200
SUBMISSION SIGNATURE /Jan N. Tittel/
SIGNATORY'S NAME Jan N. Tittel
SIGNATORY'S POSITION Attorney of record, Massachusetts bar member
DATE SIGNED 03/31/2020
SIGNATORY'S PHONE NUMBER 6174280200
AUTHORIZED SIGNATORY YES
FILING INFORMATION
SUBMIT DATE Tue Mar 31 10:38:39 ET 2020
TEAS STAMP USPTO/SOU-XX.XXX.X.XXX-20
200331103839135414-882768
35-7109acc8bfb91af4c3029f
4613a525b65b580f5143a18a0
c71a3840fb329e6e8853-DA-3
8383862-20200331103349202
373



Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1553 (Rev 09/2005)
OMB No. 0651-0054 (Exp 12/31/2020)


Trademark/Service Mark Statement of Use
(15 U.S.C. Section 1051(d))


To the Commissioner for Trademarks:
MARK: PLATO(Standard Characters, see http://tmng-al.gov.uspto.report/resting2/api/img/88276835/large)
SERIAL NUMBER: 88276835
An Extension of Time form is being filed with the Allegation of Use.


OWNER AND/OR ENTITY INFORMATION
The owner proposes to amend the following:
Current: AVROBIO, Inc., having an address of
      Building 300, Suite 201
      One Kendall Square
      Cambridge, Massachusetts 02139
      United States
Proposed: AVROBIO, Inc., having an address of
      Building 300, Suite 201
      One Kendall Square
      Cambridge, Massachusetts 02139
      United States
      Phone:
      Email: XXXX

The owner is submitting the following allegation of use information:

For International Class 005:
Current identification: Pharmaceuticals for treatment of rare and other diseases, namely, autoimmune diseases, diseases of the central nervous system, and oncological diseases

All ITU goods/services in this class are to be deleted or processed according to a request to divide.


For International Class 042:
Current identification: Platform as a service (PAAS) featuring gene therapy development platforms for treatments for rare and other diseases

The mark is in use in commerce on or in connection with all of the goods/services, or to indicate membership in the collective organization listed in the application or Notice of Allowance or as subsequently modified for this specific class.

The mark was first used by the applicant, or the applicant's related company, licensee, or predecessor in interest at least as early as 03/00/2020, and first used in commerce at least as early as 03/00/2020, and is now in use in such commerce. The applicant is submitting one specimen for the class showing the mark as used in commerce on or in connection with any item in the class, consisting of a(n) Image of applicant website showing platform as a service (PAAS) featuring gene therapy development platforms for treatments for rare and other diseases.

Original PDF file:
SPN1-382423194-20200330111050057681_._PLATO.pdf
Converted PDF file(s) (2 pages)
Specimen File1
Specimen File2


REQUEST TO DIVIDE
The applicant is requesting to divide the application and specifies the following:
The following good(s) or service(s) is/are now in use: Platform as a service (PAAS) featuring gene therapy development platforms for treatments for rare and other diseases
The following good(s) or service(s) remain(s) under the Section 1(b), intent to use basis: Pharmaceuticals for treatment of rare and other diseases, namely, autoimmune diseases, diseases of the central nervous system, and oncological diseases

The owner's/holder's current attorney information: Michael J. Belliveau. Michael J. Belliveau of CLARK+ELBING LLP, is located at

      101 FEDERAL STREET, 15TH FLOOR
      BOSTON, Massachusetts 02110
      United States
The docket/reference number is 51182-T02001.

The phone number is 617-428-0200.

The fax number is 6174287045.

The email address is cedocket@clarkelbing.com

The owner's/holder's proposed attorney information: Michael J. Belliveau. Other appointed attorneys are Paul T. Clark, Karen L. Elbing, James D. DeCamp, Susan M. Michaud, J. Cooper McDonald, Richard Todd Armstrong, Jeffrey J. Ellison, Jan N. Tittel, Andrew R. Germain, Thomas J. Takara, Adil Zhugralin. Michael J. Belliveau of CLARK+ELBING LLP, is a member of the XX bar, admitted to the bar in XXXX, bar membership no. XXX, and the attorney(s) is located at

      101 FEDERAL STREET, 15TH FLOOR
      BOSTON, Massachusetts 02110
      United States
The docket/reference number is 51182-T02001.

The phone number is 617-428-0200.

The fax number is 6174287045.

The email address is cedocket@clarkelbing.com

Michael J. Belliveau submitted the following statement: The attorney of record is an active member in good standing of the bar of the highest court of a U.S. state, the District of Columbia, or any U.S. Commonwealth or territory.Correspondence Information (current):
      MICHAEL J. BELLIVEAU
      PRIMARY EMAIL FOR CORRESPONDENCE: cedocket@clarkelbing.com
      SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): NOT PROVIDED

The docket/reference number is 51182-T02001.
Correspondence Information (proposed):
      Michael J. Belliveau
      PRIMARY EMAIL FOR CORRESPONDENCE: cedocket@clarkelbing.com
      SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): NOT PROVIDED

The docket/reference number is 51182-T02001.

Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the applicant owner/holder and the applicant owner's/holder's attorney, if appointed, and that all official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).

A fee payment in the amount of $100 will be submitted with the form, representing payment for the allegation of use for 1 class.

A fee payment in the amount of $100 will be submitted with the form, representing payment for the request to divide fee.


Declaration


The signatory believes that the applicant is the owner of the mark sought to be registered.
For a trademark or service mark application, the mark is in use in commerce on or in connection with all the goods/services in the application or notice of allowance, or as subsequently modified.
For a collective trademark, collective service mark, collective membership mark application, the applicant is exercising legitimate control over the use of the mark in commerce by members on or in connection with all the goods/services/collective membership organization in the application or notice of allowance, or as subsequently modified.
For a certification mark application, the applicant is exercising legitimate control over the use of the mark in commerce by authorized users on or in connection with the all goods/services in the application or notice of allowance, or as subsequently modified, and the applicant is not engaged in the production or marketing of the goods/services to which the mark is applied, except to advertise or promote recognition of the certification program or of the goods/services that meet the certification standards of the applicant.
The specimen(s) shows the mark as used on or in connection with the goods/services/collective membership organization in commerce.
To the best of the signatory's knowledge and belief, no other persons, except, if applicable, authorized users, members, and/or concurrent users, have the right to use the mark in commerce, either in the identical form or in such near resemblance as to be likely, when used on or in connection with the goods/services/collective membership organization of such other persons, to cause confusion or mistake, or to deceive.
To the best of the signatory's knowledge, information, and belief, formed after an inquiry reasonable under the circumstances, the allegations and other factual contentions made above have evidentiary support.
The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001, and that such willful false statements and the like may jeopardize the validity of the application or submission or any registration resulting therefrom, declares that all statements made of his/her own knowledge are true and all statements made on information and belief are believed to be true.



Signature: /Jan N. Tittel/      Date Signed: 03/31/2020
Signatory's Name: Jan N. Tittel
Signatory's Position: Attorney of record, Massachusetts bar member
Signatory's Phone: 6174280200

Request to Divide Signature


Signature: /Jan N. Tittel/    Date: 03/31/2020
Signatory's Name: Jan N. Tittel
Signatory's Position: Attorney of record, Massachusetts bar member

Signatory's Phone: 6174280200

The signatory has confirmed that he/she is a U.S.-licensed attorney who is an active member in good standing of the bar of the highest court of a U.S. state (including the District of Columbia and any U.S. Commonwealth or territory); and he/she is currently the owner's/holder's attorney or an associate thereof; and to the best of his/her knowledge, if prior to his/her appointment another U.S.-licensed attorney not currently associated with his/her company/firm previously represented the owner/holder in this matter: the owner/holder has revoked their power of attorney by a signed revocation or substitute power of attorney with the USPTO; the USPTO has granted that attorney's withdrawal request; the owner/holder has filed a power of attorney appointing him/her in this matter; or the owner's/holder's appointed U.S.-licensed attorney has filed a power of attorney appointing him/her as an associate attorney in this matter.


Mailing Address:
   CLARK+ELBING LLP
   
   101 FEDERAL STREET, 15TH FLOOR
   BOSTON, Massachusetts 02110

RAM Sale Number: 88276835
RAM Accounting Date: 03/31/2020

Serial Number: 88276835
Internet Transmission Date: Tue Mar 31 10:38:39 ET 2020
TEAS Stamp: USPTO/SOU-XX.XXX.X.XXX-20200331103839135
414-88276835-7109acc8bfb91af4c3029f4613a
525b65b580f5143a18a0c71a3840fb329e6e8853
-DA-38383862-20200331103349202373



Statement of Use [image/jpeg]

Statement of Use [image/jpeg]

Statement of Use [image/jpeg]


uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed